22 Boston Wharf Road
Floor 7
Boston, MA 02210
United States
929 274 7510
https://www.akaritx.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 9
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. Samir Rashmikant Patel M.D. | Interim CEO & Director | 3.7k | N/D | 1969 |
Ms. Wendy F. DiCicco CPA | Interim Chief Financial Officer | 540.34k | N/D | 1967 |
Dr. Miles Nunn | Chief Scientific Officer | N/D | N/D | 1969 |
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts.
La calificación ISS Governance QuickScore de Akari Therapeutics, Plc a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.